CD47 and cancer: Furthermore, given the significant immune-related adverse events associated with existing cancer immunotherapies targeting self-nonself recognition signals, such as the PD1-PDL1 interaction and SIRPα-CD47 87,88, the development of therapies centered on MCS and clock genes may offer a solution to these challenges in cancer immunotherapy.